PFG Advisors Sells 189 Shares of Church & Dwight Co., Inc. (NYSE:CHD)

PFG Advisors lowered its holdings in Church & Dwight Co., Inc. (NYSE:CHD) by 0.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,337 shares of the company’s stock after selling 189 shares during the period. PFG Advisors’ holdings in Church & Dwight were worth $3,177,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of CHD. CWA Asset Management Group LLC acquired a new position in shares of Church & Dwight in the 3rd quarter valued at approximately $241,000. Covestor Ltd raised its position in shares of Church & Dwight by 62.0% in the 3rd quarter. Covestor Ltd now owns 682 shares of the company’s stock valued at $71,000 after buying an additional 261 shares in the last quarter. Axxcess Wealth Management LLC raised its position in shares of Church & Dwight by 3.0% in the 3rd quarter. Axxcess Wealth Management LLC now owns 10,022 shares of the company’s stock valued at $1,049,000 after buying an additional 293 shares in the last quarter. Crossmark Global Holdings Inc. raised its position in shares of Church & Dwight by 4.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 11,336 shares of the company’s stock valued at $1,187,000 after buying an additional 431 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in shares of Church & Dwight in the 3rd quarter valued at approximately $28,000. Institutional investors own 86.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CHD. Royal Bank of Canada restated a “sector perform” rating and issued a $105.00 target price on shares of Church & Dwight in a research report on Monday, February 3rd. Stifel Nicolaus boosted their target price on shares of Church & Dwight from $103.00 to $105.00 and gave the company a “hold” rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. lowered their price objective on shares of Church & Dwight from $107.00 to $106.00 and set an “underweight” rating for the company in a research report on Friday, February 21st. Piper Sandler lowered their price objective on shares of Church & Dwight from $128.00 to $126.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Finally, Truist Financial upped their price objective on shares of Church & Dwight from $110.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $111.56.

Insider Activity

In related news, EVP Maynadier Patrick D. De sold 54,510 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $115.98, for a total transaction of $6,322,069.80. Following the transaction, the executive vice president now directly owns 10,497 shares of the company’s stock, valued at $1,217,442.06. This represents a 83.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Read bought 1,100 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were bought at an average cost of $106.82 per share, for a total transaction of $117,502.00. Following the completion of the purchase, the executive vice president now owns 2,505 shares of the company’s stock, valued at $267,584.10. This represents a 78.29 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 64,510 shares of company stock valued at $7,383,170. 1.40% of the stock is currently owned by insiders.

Church & Dwight Trading Down 2.8 %

Shares of NYSE CHD opened at $109.04 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.70. Church & Dwight Co., Inc. has a 52-week low of $96.35 and a 52-week high of $116.46. The firm has a 50 day moving average price of $106.64 and a two-hundred day moving average price of $105.57. The stock has a market cap of $26.82 billion, a P/E ratio of 46.01, a price-to-earnings-growth ratio of 3.32 and a beta of 0.57.

Church & Dwight (NYSE:CHD) last announced its quarterly earnings results on Friday, January 31st. The company reported $0.77 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.77. Church & Dwight had a net margin of 9.58% and a return on equity of 20.03%. During the same period in the previous year, the company posted $0.65 earnings per share. As a group, equities analysts forecast that Church & Dwight Co., Inc. will post 3.7 EPS for the current year.

Church & Dwight Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a $0.295 dividend. This is a positive change from Church & Dwight’s previous quarterly dividend of $0.28. This represents a $1.18 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date was Friday, February 14th. Church & Dwight’s dividend payout ratio is currently 49.79%.

Church & Dwight Profile

Church & Dwight Co, Inc engages in the development, manufacture, and marketing of household, personal care, and specialty products. It operates through the following segments: Consumer Domestic, Consumer International, Specialty Products, and Corporate. The Consumer Domestic segment offers household products, such as laundry detergents, fabric softener sheets, cat litter, and household cleaning products, and personal care products including antiperspirants, oral care products, depilatories, reproductive health products, oral analgesics, nasal saline moisturizers, and dietary supplements.